Bizarre Patents
An electrified table cloth for preventing crawling insects from gaining access to the consumer's food or drink.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Application No. | Application Title | Issue Date |
| 20120128766 | Self-Breaking Tablets Self-breaking core tablets and functionally coated tablets and capsule formulations are provided. Methods for production of these tablet and capsule formulations and their administration are also provided.... | 05/24/2012 |
| 20120104039 | Medicament/Dosimeter Combination Packaging A system for individual dosing of a medicament, in accordance with the individual pathological properties (“fingerprint”) of a patient—corresponding physiologically or genetically to the disease status is based on two components: the medicament that is to be taken... | 05/03/2012 |
| 20120034270 | S1P Receptors Modulators The invention relates to novel compounds that have S1P receptor modulating activity and, preferably, apoptotic activity and/or anti proliferative activity against cancer cells and other cell types. Further, the invention relates to a pharmaceutical comprising at least o... | 02/09/2012 |
| 20120010245 | TRANSDERMAL PHARMACEUTICAL COMPOSITIONS COMPRISING A SERM The present invention relates to transdermal pharmaceutical compositions such as gels containing a SERM selected from the group consisting of endoxifen, droloxifene, clomifene, raloxifene, tamoxifen, 4-OH tamoxifen, toremifene, danazol and the pharmaceutically acceptabl... | 01/12/2012 |
| 20120003316 | TRANSMUCOSAL DELIVERY SYSTEM This invention relates to a multi-configured, transmucosal pharmaceutical dosage form and, more particularly, to a pharmaceutical dosage form which has a single monolithic/heterogeneous layer or a plurality of such layers. The dosage form is suitable for the delivery of... | 01/05/2012 |
| 20110319483 | 1-ADAMANTYL CHALCONES FOR THE TREATMENT OF PROLIFERATIVE DISORDERS The present invention relates to the compounds of the general formula (I), a composition for and a method of treating breast cancer or other proliferative disorders in a subject using a compound of general formula [I], | 12/29/2011 |
| 20110318411 | MULTI-LAYERED ORALLY DISINTEGRATING TABLET AND THE MANUFACTURE THEREOF The present invention features a tablet containing a first layer and a second layer, wherein: (i) the first layer includes a pharmaceutically active agent and the composition of the first layer is different from the composition of the second layer; (ii) the tablet has a... | 12/29/2011 |
| 20110319441 | MANUFACTURE OF VARIABLE DENSITY DOSAGE FORMS UTILIZING RADIOFREQUENCY ENERGY The present invention features the present invention features a tablet including at least one pharmaceutically active ingredient, wherein the shape of said tablet includes at least one major face wherein: (i) the peak penetration resistance at the perimeter of said majo... | 12/29/2011 |
| 20110293673 | ORAL FILM-FORM BASE AND ORAL FILM-FORM PREPARATION The present invention provides a film-form base having one or more sugars or sugar alcohols dispersed as fine particles therein, and also provides a film-form preparation containing the base and a drug. The base is produced by dispersing, in an organic solvent having a ... | 12/01/2011 |
| 20110288113 | METHOD TO REDUCE OR ELMINATE THE USE BY A PATIENT OF A TOLERANCE-INDUCING PHARAMACOLOGICAL AGENT A multiple total daily dose regimen is developed in order to decrease the use by a patient of a tolerance-inducing pharmacological agent. In one example, the method reduces or phases out altogether a patient's chronic use of opioid drugs by use of a successive reduction... | 11/24/2011 |
| 20110289605 | Animal Model for Osteoarthritis and Intervertebral Disc Disease Provided herein is a transgenic animal whose genome comprises a first nucleic acid sequence encoding a fusion polypeptide, wherein the fusion polypeptide comprises a Cre recombinase and a mutated ligand binding domain of human estrogen receptor (CreER), wherein the firs... | 11/24/2011 |
| 20110280909 | METHOD AND SYSTEM FOR EFFECTING CHANGES IN PIGMENTED TISSUE Methods and systems are described for a rapid and sustainable change in the pigment melanin content of melanocytes of the iris stroma, thereby to change the color of the eye. Also described are nanoparticle compositions for lightening the pigmented tissues or treating a... | 11/17/2011 |
| 20110281952 | DEUTERIUM-ENRICHED TOLTERODINE The present application describes deuterium-enriched tolterodine, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... | 11/17/2011 |
| 20110274740 | METHODS OF REDUCING SYMPTOMS IN SUBJECTS USING SINGLE DOSAGE FORMS WITH TAPERING RELEASE RATES The present invention is directed to methods of reducing symptoms associated with an abrupt reduction in an endogenous or exogenous chemical in subjects, the methods comprising: (a) administering to the subject a single dosage form comprising an active agent, wherein th... | 11/10/2011 |
| 20110275616 | Combination Analgesic Employing Opioid and Neutral Antagonist Methods of utilizing an opioid agonist in a mammalian subject in a manner that inhibits peripheral effects of the opioid agonist are described. The methods comprise administering the opioid agonist in an amount sufficient to confer analgesia the subject and co-administe... | 11/10/2011 |
| 20110268820 | USE OF SELECTIVE ESTROGEN RECEPTOR MODULATOR FOR JOINT FUSION AND OTHER REPAIR OR HEALING OF CONNECTIVE TISSUE Methods for facilitating joint immobilization or fusion using selective estrogen receptor modulator (SERM) such as raloxifene are disclosed. The SERM may be administered systemically or locally. In conjunction with SERM, other therapeutic agents such as calcium, vitamin... | 11/03/2011 |
| 20110269841 | THIN FILM WITH METHADONE ACTIVE INGREDIENT An orally dissolvable thin film strip for the administration of the pharmaceutical active Methadone is formed by mixing a wet slurry of a water-soluble polymer, a polar solvent, Methadone HCl, and optional additives. The slurry is then cast onto a substrate by slot die ... | 11/03/2011 |
| 20110244051 | PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT OF OVERACTIVE BLADDER Disclosed herein are pharmaceutical compositions comprising a plurality of first beads each comprising: a core; a first layer comprising pilocarpine or a pharmaceutically acceptable salt thereof; and a second layer comprising a first polymer. Also disclosed are pharmace... | 10/06/2011 |
| 20110245208 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF SOMATOSENSORY DISORDERS A method of combating a somatosensory disorder in a subject, comprising administering to the subject an effective amount of a composition comprising bupranolol and/or pharmaceutically acceptable derivative(s) thereof. Compositions useful for such administration are desc... | 10/06/2011 |
| 20110237615 | Narcotic Drug Formulations with Decreased Abuse Potential The present application relates to novel narcotic formulations having a decreased injection abuse potential In a representative embodiment, the formulation comprises methadone hydrochloride (6-dimethylamino-4,4-diphenylheptan-3-one, a synthetic opio... | 09/29/2011 |
| 20110229468 | TARGETING PAX2 FOR THE TREATMENT OF BREAST CANCER The present application provides methods of prevention and/or treatment of breast cancer in a subject by inhibiting expression of PAX2. In the cancer treatment methods disclosed, the method of inhibiting expression of PAX2 can be by administration of a nucleic acid enco... | 09/22/2011 |
| 20110229467 | TARGETING PAX2 FOR THE TREATMENT OF BREAST CANCER The present application provides methods of prevention and/or treatment of breast cancer in a subject by inhibiting expression of PAX2. In the cancer treatment methods disclosed, the method of inhibiting expression of PAX2 can be by administration of a nucleic acid enco... | 09/22/2011 |
| 20110217341 | METHOD FOR PREPARING MICROSPHERES AND MICROSPHERES PRODUCED THEREBY The present invention relates to a method for preparing microspheres and microspheres prepared thereby, more particularly to a method for preparing a polymeric microsphere, including preparing an emulsion including a polymer compound, a drug, a water-insoluble organic s... | 09/08/2011 |
| 20110217383 | PH-DEPENDENT CONTROLLED RELEASE PHARMACEUTICAL OPIOID COMPOSITION WITH RESISTANCE AGAINST THE INFLUENCE OF ETHANOL The invention relates to a pH-dependent controlled release pharmaceutical composition, comprising a core, and an opioid, wherein the core is coated at least by one coating layer, controlling the release of the pharmaceutical composition, wherein the coating layer compri... | 09/08/2011 |
| 20110206666 | TARGETING PAX2 FOR THE TREATMENT OF BREAST CANCER The present application provides methods of prevention and/or treatment of breast cancer in a subject by inhibiting expression of PAX2. In the cancer treatment methods disclosed, the method of inhibiting expression of PAX2 can be by administration of a nucleic acid enco... | 08/25/2011 |
| 20110200695 | GEL COMPOSITION FOR FILLING A BREAST MILK DUCT PRIOR TO SURGICAL EXCISION OF THE DUCT OR OTHER BREAST TISSUE The invention is a gel composition for delivery to a breast milk duct prior to surgical excision of breast tissue including cancerous lesions. The invention also provides methods of mapping all or nearly all of a breast milk duct prior to surgical excision of breast tis... | 08/18/2011 |
| 20110182857 | Delivery of Drugs to Mucosal Surfaces Liquid pharmaceutical compositions for administration to a mucosal surface, including a therapeutic agent and a pectin with a low degree of esterification are described. Such compositions gel, or can be adapted to gel, at the site of application in the absence of an ext... | 07/28/2011 |
| 20110177138 | ALCOHOL-RESISTANT SUSTAINED-RELEASE ORAL PHARMACEUTICAL FORM BASED ON MICROGRANULES Oral pharmaceutical form containing microgranules for the sustained release of at least one active principle, including a neutral carrier that is insoluble in water or in an alcohol solution, or a neutral carrier rendered insoluble in water or an alcohol solution, compr... | 07/21/2011 |
| 20110165234 | EXTENDED RELEASE VENLAFAXINE FORMULATION A controlled release dosage form of venlafaxine that comprises an immediate release pellet and an extended release pellet.... | 07/07/2011 |
| 20110159094 | EXTENDED RELEASE COMPOSITIONS FOR HIGH SOLUBILITY, HIGH PERMEABILITY ACTIVE PHARMACEUTICAL INGREDIENTS A novel composition comprising a tablet, comprising a highly soluble active pharmaceutical ingredient, which is then coated with a coating. The core is preferably a tablet. The coating preferably comprises any type of suitable extended release polymer, with the proviso ... | 06/30/2011 |
| 20110160186 | Methods of Treating CYP2D6 Alternative Metabolizers The invention provides various methods comprising the administration of a CYP2D6 bioactive drug covalently bound to a water-soluble oligomer. Metabolism of CYP2D6 bioactive drug conjugates is diverted from CYP2D6 to alternative pathways, and the conjugates may therefore... | 06/30/2011 |
| 20110152227 | DEUTERIUM LABELLED DERIVATIVES OF 3-(2-HYDROXY-5-METHYPHENYL)-N,N-DIISOPROPYL-3-PHENYLPROPYLAMINE AND METHODS OF USE THEREOF This invention relates to novel derivatives of tolterodine, 5-hydroxymethyl tolterodine, fesoterodine and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in met... | 06/23/2011 |
| 20110150937 | EXTENDED RELEASE COMPOSITIONS COMPRISING TOLTERODINE The present invention deals with extended release pharmaceutical composition comprising tolterodine, wherein the composition comprises of: a) a drug layer comprising of drug tolterodine tartrate, monosaccharide and/or disaccharide on an inert core; or a drug core compri... | 06/23/2011 |
| 20110150979 | METHODS FOR DIAGNOSIS, PROGNOSIS AND TREATMENT OF PRIMARY AND METASTATIC BASAL-LIKE BREAST CANCER AND OTHER CANCER TYPES In one embodiment, a method of theranostic classification of a breast cancer tumor is provided, comprising obtaining a breast cancer tumor sample from a subject, detecting an expression level of FOXC1, comparing the expression level of FOXC1 to a predetermined cutoff le... | 06/23/2011 |
| 20110142828 | TREATMENT PREDICTION INVOLVING HMGCR The present invention provides a method for determining whether a mammalian subject having a breast cancer is likely to benefit from an endocrine treatment, comprising the steps of: providing a sample earlier obtained from said subject; evaluating the amount of HMGCR pr... | 06/16/2011 |
| 20110142799 | MODULATION OF NEURODEGENERATIVE DISEASE BY MODULATING XBP-1 ACTIVITY The invention provides methods for treating and preventing a neurodegenerative disease associated with aberrant protein aggregation by modulating the expression and/or activity of XBP-1, IRE-1 alpha, and/or EDEM. The present invention also pertains to methods for identi... | 06/16/2011 |
| 20110142939 | Use of a Combination of an Opioid Agonist and an Opioid Antagonist for the Treatment of Crohn's Disease and the Symptoms Associated with Crohn's Disease The present invention is concerned with the use of combinations of opioid agonists and antagonists for treating Crohn's disease.... | 06/16/2011 |
| 20110136913 | ASSESSING AND TREATING BREAST CANCER PATIENTS This document provides methods and materials related to assessing and treating breast cancer patients. For example, methods and materials that involve assessing a breast cancer patient to determine whether the patient has (1) cancer cells that over express HER-2 polypep... | 06/09/2011 |
| 20110129530 | Compressible-Coated Pharmaceutical Compositions and Tablets and Methods of Manufacture There is provided a method for preparing a pharmaceutical composition comprising compressible coated, taste-masked and/or controlled-release coated drug-containing particles, rapidly-dispersing microgranules comprising a disintegrant and a sugar alcohol, a saccharide, o... | 06/02/2011 |
| 20110123610 | EXTENDED RELEASE COMPOSITIONS CONTAINING TOLTERODINE AND PROCESS FOR PREPARING THE SAME The present invention is directed to an extended release pharmaceutical composition such as tablets and capsules, and in particular to a matrix tablet composition comprising a therapeutically effective quantity of Tolterodine or pharmaceutical acceptable salts thereof i... | 05/26/2011 |
